Clinical Trials Logo

Influenza, Human clinical trials

View clinical trials related to Influenza, Human.

Filter by:

NCT ID: NCT03813966 Completed - Clinical trials for Influenza Viral Infections

Nasal Swab Home Collection Kit (NSHC Kit) Study

Start date: February 7, 2019
Phase:
Study type: Observational

The purpose of this study is to demonstrate that persons over the age of 13 years can obtain a self-collected nasal swab reliably and safely for subsequent use in the diagnosis of influenza. Similarly, the purpose is to demonstrate that parents or guardians can safely and effectively collect nasal swab specimens from children, ages 0 through 12 years, and others needing assistance in doing so, and that these parent/guardian-collected nasal swabs can also be used in the diagnosis of influenza. Clinical performance of the swabs will be based on the comparison of the performance of the nasal swab that is self- or parent/guardian-collected to one collected from the same specimen donor by a skilled clinical coordinator and used in CLIA (Clinical Laboratory Improvement Amendments)-waived, rapid diagnostic test called Sofia Influenza A+B FIA (fluorescence immunoassay analyzer).

NCT ID: NCT03784885 Completed - Influenza Infection Clinical Trials

A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult

Start date: September 1, 2017
Phase: Phase 2
Study type: Interventional

The objectives of this phase 2 study are to evaluate immunogenicity, safety and tolerability of AD07030, a trivalent influenza virus antigens vaccine, given intranasally in 2 doses in healthy adult volunteers.

NCT ID: NCT03777163 Completed - Influenza Clinical Trials

Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine

Start date: April 22, 2019
Phase: Phase 4
Study type: Interventional

The overall aim of this study is to evaluate the safety and immunogenicity of Butantan Institute Trivalent Seasonal Influenza Vaccine in comparison with the Sanofi Trivalent Seasonal Influenza Vaccine.

NCT ID: NCT03768596 Completed - Influenza, Human Clinical Trials

Nudging for Vaccination : Efficacity and Acceptability Among Medical Students

Start date: November 7, 2018
Phase: N/A
Study type: Interventional

Nudge is a set of methods aimed at helping people adopt a behavior by a gentle prompt, conscious or not. Classically, Nudges rely on heuristics and cognitive biases. These methods have been studied for years in social psychology and are receiving renewed attention since the awarding of the Nobel Prize in economics to Richard Thaler for his work on the application of Nudge to the economy. Health professionals are very inadequately vaccinated (25 to 45% of the population). Some studies have shown that a Nudge based on intent implementation can significantly increase vaccination coverage. However, few studies evaluate the acceptability of Nudge or its application to health professionals. The investigators sought to apply a Nudge based on availability heuristics to health professionals, in order to evaluate its effectiveness and terms of behavior adoption (influenza vaccination) and its acceptability. The investigator's hypothesis is that Nudging is both effective and acceptable and that people found nudging more acceptable if they have been exposed to a nudge.

NCT ID: NCT03765437 Completed - Influenza Clinical Trials

Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam

GQM10
Start date: January 15, 2019
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to describe the safety of the Quadrivalent Influenza Vaccine (QIV). Safety is assessed throughout the study period, and includes solicited injection site and systemic reactions (Day 0 to Day 7 post-vaccination); unsolicited adverse events up to Day 28, and serious adverse events occurring throughout the study.

NCT ID: NCT03757546 Completed - Influenza Clinical Trials

Extra-pulmonary Clinical Manifestations of Influenza Virus and Respiratory Syncitial Virus Infections

GIVRE
Start date: December 3, 2018
Phase:
Study type: Observational

The purpose of this study is to describe extra-pulmonary clinical manifestations of Influenza virus and Respiratory Syncitial Virus infections in hospitalized adults at a French university hospital.

NCT ID: NCT03748160 Completed - Influenza, Human Clinical Trials

Herd Immunity and Influenza Vaccine Uptake

HIIVU
Start date: October 1, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to test the effectiveness of communicating the concept of herd immunity on actual influenza vaccine uptake using a randomized controlled trial.

NCT ID: NCT03745274 Completed - Influenza, Avian Clinical Trials

Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults

Start date: December 19, 2008
Phase: Phase 1
Study type: Interventional

This study evaluates safety, tolerability and immunogenicity of two doses of GHB04L1, a liquid formulation of the replication- deficient influenza A/Vietnam/1203/04(H5N1)-like ∆NS1 virus in healthy adults. Subjects are randomised at a ratio of 2:1 for GHB04L1 (6.8 log10 or 7.5 log10 TCID50/dose/volunteer) or placebo.

NCT ID: NCT03744104 Completed - Influenza Clinical Trials

A Clinical Trial of A Quadrivalent Influenza Vaccine

Start date: October 11, 2018
Phase: Phase 3
Study type: Interventional

The aim of this study is to assess the immunogenicity and safety of a quadrivalent influenza vaccine compared with a trivalent influenza vaccine in participants aged above 3 years.

NCT ID: NCT03743688 Completed - Influenza Clinical Trials

Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults

KIRV
Start date: December 4, 2018
Phase:
Study type: Observational

The purpose of this study is to evaluate the body's immune response at different time points to an FDA-approved seasonal influenza vaccine. By better understanding the way the immune system responds to the influenza vaccine, the investigators can design more effective vaccines against influenza.